What company makes Wegovy — and why it matters for your treatment

Novo Nordisk: the company behind semaglutide

Novo Nordisk is headquartered in Bagsværd, Denmark, and has operated in the UK market for decades. The company built its reputation on insulin production before expanding into GLP-1 medicines. Semaglutide (the molecule at the heart of Wegovy) was developed by Novo Nordisk's research teams and first approved for type 2 diabetes before a higher-dose weight-management formulation was studied and licensed separately.

A common assumption is that Ozempic and Wegovy are interchangeable because they share an ingredient. They are not. Ozempic (also semaglutide, also by Novo Nordisk) carries a UK licence for type 2 diabetes. Wegovy is the distinct licensed product for weight management, at a different dose and with its own clinical evidence base. The MHRA licenses each product individually, and prescribing for the wrong indication falls outside those licences. That distinction is not a technicality, it affects clinical monitoring, dose schedules and what support you should receive alongside treatment.

You can read about the clinical evidence for semaglutide on the NHS semaglutide medicines page, which covers both the mechanism and what patients can expect. Novo Nordisk, the Wegovy company, also publishes prescribing information at novonordisk.co.uk for healthcare professionals who want the full detail.

What the manufacturer's identity tells you about supply chain safety

The reason knowing the manufacturer matters is straightforward: genuine Wegovy comes from the company that makes Wegovy, Novo Nordisk, through the authorised UK supply chain. It does not come from compounding pharmacies, social-media sellers, or websites that skip the prescription stage entirely. The MHRA has warned publicly about counterfeit and unlicensed weight-loss pens circulating in the UK, fake pens have on occasion contained the wrong active substance, posing real clinical risk.

A genuinely low price for Wegovy should prompt a question, not a click. If a seller is offering semaglutide without requiring a clinical consultation and a valid prescription, they are operating outside UK law and the product almost certainly has not travelled through Novo Nordisk's licensed distribution. The safe route is a pharmacy you can verify on the GPhC register. At nume (sorry, at the service level) this is precisely why sourcing through the licensed supply chain is a stated part of how we operate, not a footnote.

At nume, medicines are sourced through the licensed UK supply chain, and our GPhC-registered pharmacy (registration number 9012878) is verifiable on the GPhC register.

The decision you're actually facing: who makes this medicine, and who prescribes it for me

Most people searching for what company Wegovy is made by are trying to answer a bigger question: can I trust this product, and can I get it legitimately? Those are exactly the right questions. Novo Nordisk manufactures the medicine; a GPhC-registered prescriber decides whether it is suitable for you. The two roles are separate, and both matter.

Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The prescriber weighs your full medical picture, not just a number on a scale. For detail on the broader treatment landscape, the Wegovy treatment page covers eligibility, the dose schedule and what to expect.

NICE's appraisal of semaglutide for weight management (NICE TA875) sets out the conditions under which the NHS recommends it, useful reading if you are weighing NHS versus private routes. Private access through a regulated pharmacy does not require those specific NHS criteria to be met, though the medicine remains prescription-only and clinical suitability still applies.

The oral version: what Novo Nordisk's newest approval means

In June 2026 the MHRA approved semaglutide tablets under the Wegovy name, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. The tablet formulation uses an absorption enhancer called SNAC to allow the drug to work when swallowed rather than injected. It is taken once daily, first thing in the morning on an empty stomach.

The molecule is the same one Novo Nordisk has spent years refining; the delivery method is new. Trial data from the OASIS 4 study reported an average weight reduction of around 13.6% over 64 weeks, and around 17% among participants who adhered fully to treatment, though that figure should be understood as the adherent-only result rather than the general average. Common side effects were predominantly gastrointestinal, consistent with the injectable version, and were generally mild to moderate.

If you want to explore both the injection and tablet options together, our weight-loss treatment overview covers them side by side. Questions about which format suits your routine (or whether either is appropriate given your health history) are exactly what our prescribers are there to answer. You can also read more about semaglutide as a medicine before deciding whether to take the next step.